Autolus moves forward with novel CAR-T therapy candidate – The Pharma Letter
The Pharma Letter |
Autolus moves forward with novel CAR–T therapy candidate
The Pharma Letter UK-based immuno-oncology startup Autolus has pulled the trigger on a licensing agreement to acquire global rights from UCL Business to develop and commercialize a novel CAR–T cell therapy targeting B cell malignancies. Autolus was launched in 2015 with … |
